Abstract:
The present invention provides a compounds 7a-f to 18a-f and 19a-f to 30a-f of general formula A, useful as potential anticancer agents against human cancer cell lines. The present invention further provides a process for the preparation of imidazothiazole-chalcone hybrids 7a-f to 18a-f and 19a-f to 30a-f of general formula A 
                                 
wherein

Description:
RELATED APPLICATIONS 
     The present application is a National Phase of International Application Number PCT/IB2010/002544, filed Oct. 7, 2010, and claims priority from, Indian Application Number 2121/DEL/2009, filed Oct. 13, 2009. 
     The following specification particularly describes the invention and the manner in which it is to be performed: 
     FIELD OF THE INVENTION 
     The present invention relates to novel imidazothiazole-chalcone derivatives of general formula A. 
                                
wherein
 
     
       
                 
         
             
             
         
      
     
     The present invention also relates to the process of preparation of imidazothiazole-chalcone hybrids of general formula A. 
     The present invention also relates to (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (7a), (E)-3-(6-(4-fluorophenyl) imidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (7e), (E)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (7f), (E)-1-(3,4-dimethoxyphenyl)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl) prop-2-en-1-one (8f) and (E)-3-(6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (19e); useful as anticancer agents. 
     BACKGROUND OF THE INVENTION AND PRIOR ART 
     Many clinically successful anticancer drugs acting as antimitotics interfere with dynamic instability of microtubules; spindle poisons arrest-dividing cells in G2/M phase of the cell cycle, causing apoptotic cell death. Among the natural products affecting microtubule dynamic are colchicines, the vinca alkaloids, combretastatin A4, epothilane, and taxanes. Chalcones are the flavone precursors that possess the antimitotic activity and possess greater antiproliferative activity. Michael L. Edwards, David M. Stemerick, Prasad S. Sunkara,  J. Med. Chem.,  1990, 33 (7), 1948-1954. Ahcène Boumendjel,*, Julien Boccard, Pierre-Alain Carrupt, Edwige Nicolle, Madeleine Blanc,  J. Med. Chem.  2008, 51, 2307-2310. The anticancer activity of 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones have been reported in 1997. Similarly the new guanylhydrazones from imidazo[2,1-b]thiazoles have shown promising anticancer activity. Aldo Andreani,*, Silvia Burnelli, Massimiliano Granaiola, Alberto Leoni, Alessandra Locatelli  J. Med. Chem.  2008, 51, 809-816, Aldo Andreani,*, Silvia Burnelli, Massimiliano Granaiola, Alberto Leoni, Alessandra Locatelli,  J. Med. Chem.  2007, 50, 3167-3172, Aldo Andreani,*, Massimiliano Granaiola, Alberto Leoni, Alessandra Locatelli, Rita Morigi,  J. Med. Chem.  2005, 48, 3085-3089. Moreover the activity of chalcones was found to be dependent on both A and B rings. Hence some new hybrids were prepared by replacing the B ring in chalcone with imidazothiazole moiety, which is already well known for their antitumor activity. These hybrids have shown potent cytotoxicity in the NCI cell line screen for evaluation of their anticancer activity. 
     
       
                 
         
             
             
         
      
     
     OBJECTIVES OF THE INVENTION 
     The main objective of the present invention is to provide novel Imidazothiazole-chalcone hybrids of general formula A. 
     Another objective of the present invention is to provide novel Imidazothiazole-chalcone hybrids of general formula A, useful as anticancer agents. 
     Yet another objective of the present invention is to provide a process for the preparation of Imidazothiazole-chalcone hybrids of general formula A. 
     SUMMARY OF THE INVENTION 
     Accordingly, the present invention provides Imidazothiazole-chalcone hybrids of general formula A 
                                
wherein
 
     
       
                 
         
             
             
         
      
     
     In an embodiment, the present invention provides compounds of general formula A represent as follow:
     (7a) (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl) prop-2-en-1-one   (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl) prop-2-en-1-one; (7a)   (E)-3-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; (7b)   (E)-3-(6-(4-methoxy-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxy-phenyl)prop-2-en-1-one; (7c)   (E)-3-(6-(4-chloro-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxy-phenyl)prop-2-en-1-one; (7d)   (E)-3-(6-(4-fluorophenyl)imidazo[2, 1-1)]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; (7e)   (E)-3-(6-(trifluoromethyl)imidazo[2, 1-1)]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; (7f)   (E)-3-(6-(4-methoxyphenyl)-2-methylimidazo[2, 1-1)]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; (19a)   (E)-3-(6-(4-chlorophenyl)-2-methylimidazo[2, 1-1)]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; (19b)   (E)-3-(6-(4-methoxy-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; (19c)   (E)-3-(6-(-(4-chloro-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; (19d)   (E)-3-(6-(4-fluorophenyl)-2-methylimidazo[2, 1-1)]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; (19e)   (E)-3-(2-methyl-6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one; (19f)   (E)-1-(3,4-dimethoxyphenyl)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (8a)   (E)-3-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4-dimethoxyphenyl) Prop-2-en-1-one; (8b)   (E)-1-(3,4-dimethoxyphenyl)-3-(6-(4-methoxy-3-nitrophenyl)imidazo[2,1-b]Thiazol-5-yl)prop-2-en-1-one; (8c)   (E)-3-(6-(4-chloro-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4-dimethoxy phenyl) prop-2-en-1-one; (8d)   (E)-1-(3,4-dimethoxyphenyl)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl) Prop-2-en-1-one; (8e)   (E)-1-(3,4-dimethoxyphenyl)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl) Prop-2-en-1-one; (8f)   (E)-1-(3,4-dimethoxyphenyl)-3-(6-(4-methoxyphenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (20a)   (E)-3-(6-(4-chlorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(3,4-dimethoxy phenyl)prop-2-en-1-one; (20b)   (E)-1-(3,4-dimethoxyphenyl)-3-(6-(4-methoxy-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (20c)   (E)-3-(6-(4-chloro-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one; (20d)   (E)-1-(3,4-dimethoxyphenyl)-3-(6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl) prop-2-en-1-one; (20e)   (E)-1-(3,4-dimethoxyphenyl)-3-(2-methyl-6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (20f)   (E)-1-(3,4-dimethylphenyl)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl) prop-2-en-1-one; (9a)   (E)-3-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4-dimethylphenyl) Prop-2-en-1-one; (9b)   (E)-1-(3,4-dimethylphenyl)-3-(6-(4-methoxy-3-nitrophenyl)imidazo[2,1-b]Thiazol-5-yl)prop-2-en-1-one; (9c)   (E)-3-(6-(4-chloro-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4-dimethyl phenyl)prop-2-en-1-one; (9d)   (E)-1-(3,4-dimethylphenyl)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl) prop-2-en-1-one; (9e)   (E)-1-(3,4-dimethylphenyl)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl) prop-2-en-1-one; (9f)   (E)-1-(3,4-dimethylphenyl)-3-(6-(4-methoxyphenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (21a)   (E)-3-(6-(4-chlorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(3,4-dimethyl phenyl)prop-2-en-1-one; (21b)   (E)-1-(3,4-dimethylphenyl)-3-(6-(4-methoxy-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (21c)   (E)-3-(6-(4-chloro-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(3,4-dimethylphenyl)prop-2-en-1-one; (21d)   (E)-1-(3,4-dimethylphenyl)-3-(6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (21e)   (E)-1-(3,4-dimethylphenyl)-3-(2-methyl-6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (21f)   (E)-1-(3,5-d fluorophenyl)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazo-5-yl) prop-2-en-1-one; (10a)   (E)-3-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,5-difluorophenyl) prop-2-en-1-one; (10b)   (E)-1-(3,5-difluorophenyl)-3-(6-(4-methoxy-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (10c)   (E)-3-(6-(4-chloro-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,5-difluorophenyl)prop-2-en-1-one; (10d)   (E)-1-(3,5-difluorophenyl)-3-(6-(4-fluorophenyl)imidazo[2,1-h]thiazol-5-yl)prop-2-en-1-one; (10e)   (E)-1-(3,5-difluorophenyl)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (10f)   (E)-1-(3,5-difluorophenyl)-3-(6-(4-methoxyphenyl)-2-methyl imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (22a)   (E)-3-(6-(4-chlorophenyl)-2-methylimidazo[2,1-b thiazol-5-yl)-1-(3,5-difluoro phenyl) prop-2-en-1-one; (22b)   (E)-1-(3,5-difluorophenyl)-3-(6-(4-methoxy-3-nitrophenyl)-2-methylimidazo[2, 1-1)]thiazol-5-yl)prop-2-en-1-one; (22c)   (E)-3-(6-(4-chloro-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(3,5-difluoro phenyl)prop-2-en-1-one; (22d)   (E)-1-(3,5-difluorophenyl)-3-(6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (22e)   (E)-1-(3,5-difluorophenyl)-3-(2-methyl-6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (22f)   (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (11a)   (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (11b)   (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(6-(4-methoxy-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (11c)   (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(6-(4-chloro-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (11d)   (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (11e)   (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (11f)   (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(6-(4-methoxyphenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (23a)   (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(6-(4-chlorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (23b)   (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(6-(4-methoxy-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (23c)   (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(6-(4-chloro-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (23d)   (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (23e)   (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(2-methyl-6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (23f)   (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(naphthalen-2-yl) prop-2-en-1-one; (12a)   (E)-3-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(naphthalen-2-yl) prop-2-en-1-one; (12b)   (E)-3-(6-(4-methoxy-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(naphthalen-2-yl)prop-2-en-1-one; (12c)   (E)-3-(6-(4-chloro-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(naphthalen-2-yl)prop-2-en-1-one; (12d)   (E)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(naphthalen-2-yl)prop-2-en-1-one; (12e)   (E)-1-(naphthalen-2-yl)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (12f)   (E)-3-(6-(4-methoxyphenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(naphthalen-2-yl) prop-2-en-1-one; (24a)   (E)-3-(6-(4-chlorophenyl)-2-methyl imidazo[2,1-b]thiazol-5-yl)-1-(naphthalen-2-yl)prop-2-en-1-one; (24b)   (E)-3-(6-(4-methoxy-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(naphthalen-2-yl)prop-2-en-1-one; (24c)   (E)-3-(6-(4-chloro-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(naphthalen-2-yl)prop-2-en-1-one; (24d)   (E)-3-(6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(naphthalen-2-yl)prop-2-en-1-one; (24e)   (E)-3-(2-methyl-6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)-1-(naphthalen-2-yl)prop-2-en-1-one; (24f)   (E)-1-(biphenyl-4-yl)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (13a)   (E)-1-(biphenyl-4-yl)-3-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (13b)   (E)-1-(biphenyl-4-yl)-3-(6-(4-methoxy-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (13c)   (E)-1-(biphenyl-4-yl)-3-(6-(4-chloro-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (13d)   (E)-1-(biphenyl-4-yl)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (13e)   (E)-1-(biphenyl-4-yl)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (13f)   (E)-1-(biphenyl-4-yl)-3-(6-(4-methoxyphenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (25a)   (E)-1-(biphenyl-4-yl)-3-(6-(4-chlorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (25b)   (E)-1-(biphenyl-4-yl)-3-(6-(4-methoxy-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (25c)   (E)-1-(biphenyl-4-yl)-3-(6-(4-chloro-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (25d)   (E)-1-(biphenyl-4-yl)-3-(6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (25e)   (E)-1-(biphenyl-4-yl)-3-(2-methyl-6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (25f)   (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (14a)   (E)-3-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (14b)   (E)-3-(6-(4-methoxy-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (14c)   (E)-3-(6-(4-chloro-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (14d)   (E)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (14e)   (E)-1-(pyridin-4-yl)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (14f)   (E)-3-(6-(4-methoxyphenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (26a)   (E)-3-(6-(4-chlorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (26b)   (E)-3-(6-(4-methoxy-3-nitrophenyl)-2-methyl imidazo[2,1-b]thiazol-5-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (26c)   (E)-3-(6-(4-chloro-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (26d)   (E)-3-(6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (26e)   (E)-3-(2-methyl-6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (26f)   (E)-1-(1H-indol-3-yl)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (15a)   (E)-3-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(1H-indol-3-yl)prop-2-en-1-one; (15b)   (E)-1-(1H-indol-3-yl)-3-(6-(4-methoxy-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (15c)   (E)-3-(6-(4-chloro-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(1H-indol-3-yl)prop-2-en-1-one; (15d)   (E)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(1H-indol-3-yl)prop-2-en-1-one; (15e)   (E)-1-(1H-indol-3-yl)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (15f)   (E)-1-(1H-indol-3-yl)-3-(6-(4-methoxyphenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (27a)   (E)-3-(6-(4-chlorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(1H-indol-3-yl)prop-2-en-1-one; (27b)   (E)-1-(1H-indol-3-yl)-3-(6-(4-methoxy-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (27c)   (E)-3-(6-(4-chloro-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(1H-indol-3-yl)prop-2-en-1-one; (27d)   (E)-3-(6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(1H-indol-3-yl)prop-2-en-1-one; (27e)   (E)-1-(1H-indol-3-yl)-3-(2-methyl-6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (27f)   (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one; (16a)   (E)-3-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one; (16b)   (E)-3-(6-(4-methoxy-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one; (16c)   (E)-3-(6-(4-chloro-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one; (16d)   (E)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one; (16e)   (E)-1-(thiophen-2-yl)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (16f)   (E)-3-(6-(4-methoxyphenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one; (28a)   (E)-3-(6-(4-chlorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one; (28b)   (E)-3-(6-(4-methoxy-3-nitrophenyl)-2-methyl imidazo[2,1-b]thiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one; (28c)   (E)-3-(6-(4-chloro-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one; (28d)   (E)-3-(6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one; (28e)   (E)-3-(2-methyl-6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one; (28f)   (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one; (17a)   (E)-3-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one; (17b)   (E)-3-(6-(4-methoxy-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one; (17c)   (E)-3-(6-(4-chloro-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one; (17d)   (E)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one; (17e)   (E)-1-(1H-pyrrol-2-yl)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (17f)   (E)-3-(6-(4-methoxyphenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one; (29a)   (E)-3-(6-(4-chlorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one; (29b)   (E)-3-(6-(4-methoxy-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one; (29c)   (E)-3-(6-(4-chloro-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one; (29d)   (E)-3-(6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one; (29e)   (E)-3-(2-methyl-6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one; (29f)   (E)-1-(furan-2-yl)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (18a)   (E)-3-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(furan-2-yl)prop-2-en-1-one; (18b)   (E)-1-(furan-2-yl)-3-(6-(4-methoxy-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (18c)   (E)-3-(6-(4-chloro-3-nitrophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(furan-2-yl)prop-2-en-1-one; (18d)   (E)-1-(furan-2-yl)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (18e)   (E)-1-(furan-2-yl)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (18f)   (E)-1-(furan-2-yl)-3-(6-(4-methoxyphenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (30a)   (E)-3-(6-(4-chlorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(furan-2-yl)prop-2-en-1-one; (30b)   (E)-1-(furan-2-yl)-3-(6-(4-methoxy-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one; (30c)   (E)-3-(6-(4-chloro-3-nitrophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(furan-2-yl)prop-2-en-1-one; (30d)   (E)-3-(6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(furan-2-yl)prop-2-en-1-one; (30e)   (E)-1-(furan-2-yl)-3-(2-methyl-6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one. (30f)   

     In yet another embodiment of the present invention, Imidazothiazole-chalcone hybrids 7a, 7e, 7f, 8f and 19e exhibiting in vitro anticancer activity against human cancer cell lines selected from the group consisting of Leukemia cell lines (CCRF-CEM, MOLT-4, SR), CNS cell lines (SF-268, SF-539), Melanoma cell lines (LOX IMVI, M14, SK-MEL-5, UACC-257), Renal cell lines (A498, ACHN), lung cell lines (Hop-92), breast cell lines (MCF7, HS 578T), colon cell lines (COLO205), prostate cell lines (DU145, PC3) and ovarian cell lines (IGROV1, OVCAR-5). 
     In yet another embodiment, the concentration of the compounds 7a, 7e, 7f, 8f and 19e used for in vitro activity against leukemia cell lines for GI 50  is in the range of 1.66 to 3.08 μm, 1.55 to 2.23 μm, 0.54 to 1.92 μm, 0.49 to 2.33 μm, 1.55 to 2.23 μm and 0.80 to 7.19 μm respectively at an exposure period of at least 48 hrs. 
     In yet another embodiment, the concentration of the compounds 7a, 7e, 7f, 8f and 19e used for in vitro activity against lung cell lines for GI 50  is in the range of 0.24 to 3.70, 1.05 to 3.63, 1.65 to 7.00, 1.94 to 6.95 and 0.15 to 85.1 μm respectively at an exposure period of at least 48 hrs. 
     In yet another embodiment, the concentration of the compounds 7a, 7e, 7f, 8f and 19e used for in vitro activity against colon cell lines for GI50 is in the range of 1.77 to 3.45, 2.11 to 2.99, 1.01 to 1.94, 1.40 to 4.56 and 2.92 to 9.93 μm respectively at an exposure period of at least 48 hrs. 
     In yet another embodiment, the concentration of the compounds 7a, 7e, 7f, 8f and 19e used for in vitro activity against CNS cell lines for GI50 is in the range of 1.66 to 3.54 and 1.74 to 3.73, 1.38 to 2.67, 1.87 to 6.87 and 2.33 to 87.8 μm respectively at an exposure period of at least 48 hrs. 
     In yet another embodiment, the concentration of the compounds 7a, 7e, 7f, 8f and 19e used for in vitro activity against melanoma cell lines for GI50 is in the range of 1.30 to 5.42, 1.82 to 8.27, 1.36 to 2.26, 0.60 to 8.48 and 0.51 to 7.07 μm respectively at an exposure period of at least 48 hrs. 
     In yet another embodiment, the concentration of the compounds 7a, 7e, 7f, 8f and 19e used for in vitro activity against ovarian cell lines for GI50 is in the range of 0.21 to 4.05, 1.04 to 3.78, 1.86 to 3.08, 1.88 to 4.18, 2.28 to &gt;100 μm respectively at an exposure period of at least 48 hrs. 
     In yet another embodiment, the concentration of the compounds 7a, 7e, 7f, 8f and 19e used for in vitro activity against renal cell lines for GI50 is in the range of 1.12 to 5.04, 0.04 to 5.81, 1.56 to 2.30, 2.46 to 8.76 and 1.78 to 28.0 μM respectively, at an exposure period of at least 48 hrs. 
     In yet another embodiment, the concentration of the compounds 7a, 7e, 7f, 8f and 19e used for in vitro activity against prostate cell lines for GI50 is in the range of 2.62 to 3.10, 2.45 to 3.43, 1.41 to 2.66, 1.64 to 5.39 and 2.41 to 7.52 μm respectively at an exposure period of at least 48 hrs. 
     In yet another embodiment, the concentration of the compounds 7a, 7e, 7f, 8f and 19e used for in vitro activity against breast cell lines for IC50 is in the range of 1.90 to 3.46, 2.05 to 3.76, 1.25 to 2.92, 0.76 to 6.18 and 1.81 to 8.29 μm respectively at an exposure period of at least 48 hrs. 
     In yet another embodiment of the present invention, the invention provides a process for preparation of novel imidazothiazole-chalcone hybrids of general formula, A which includes structures from 7a-f to 18a-f and 19a-f to 30a-f, comprising the steps of:
         i. providing imidazothiazole aldehyde of formula 5;       

     
       
                 
         
             
             
         
      
         
         
           
             ii. reacting the imidazothiazole aldehyde of formula 5 with the substituted ketone of formula 6 wherein R′ represent trimethoxyphenyl, dimethoxyphenyl, dimethylphenyl, difluorophenyl, benzo[d][1,3]dioxolylnaphthalenyl, biphenyl, pyridinyl, indolyl, thiophenyl, pyrrolyl and furanyl in ethanol in the presence of 10-15% aqueous solution selected from the group consisting of sodium hydroxide, potassium hydroxide or barium hydroxide; 
           
         
       
    
     
       
                 
         
             
             
         
      
         
         
           
             iii. evaporating the organic solvent to obtain the residue which was dissolved in ethylacetate/water; 
             iv. washing the organic layer with brine and evaporated; 
             v. purifying by column chromatography to obtain the desired products of formulae 7a-f to 18a-f and 19a-f to 30a-f wherein R represent hydrogen and methyl, R′ represent trimethoxyphenyl, dimethoxyphenyl, dimethylphenyl, difluorophenyl, benzo[d][1,3]dioxolylnaphthalenyl, biphenyl, pyridinyl, indolyl, thiophenyl, pyrrolyl and furanyl and R″represent methoxyphenyl, chlorophenyl, methoxynitrophenyl, chloronitrophenyl, fluorophenyl and trifluoromethyl. 
           
         
       
    
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIG. 1  shows a process of preparation of imidazothiazole-chalcone hybrids of formula A. 
         FIG. 2  shows a structure of formula 5; and 
         FIG. 3  shows a structure of formula 6. 
     
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     The precursor imidazothiazole aldehyde of formula 5, has been prepared by using starting compounds 1 and 2 using literature methods “Aldo Andreani, Silvia Burnelli, Massimiliano Granaiola, Alberto Leoni, Alessandra Locatelli  J. Med. Chem.  2008, 51, 809-816, Aldo Andreani, Silvia Burnelli, Massimiliano Granaiola, Alberto Leoni, Alessandra Locatelli,  J. Med. Chem.  2007, 50, 3167-3172, Aldo Andreani, Massimiliano Granaiola, Alberto Leoni, Alessandra Locatelli, Rita Morigi, Mirella Rambaldi, Giorgio Lenaz, Romana Fato, Christian Bergamini, and Giovanna Farruggia  J. Med. Chem.,  2005, 48, 3085-3089 and Aldo Andreani, Silvia Burnelli, Massimiliano Granaiola, Alberto Leoni, Alessandra Locatelli, Rita Morigi, Mirella Rambaldi, Lucilla Varoli, Natalia Calonghi, Concettina Cappadone, Giovanna Farruggia, Maddalena Zini, Claudio Stefanelli, Lanfranco Masotti, Norman S. Radin and Robert H. Shoemaker,  J. Med. Chem.  2005, 48, 3085-3089.” 
     These new analogues of imidazothiazole-chalcone hybrids have shown promising anticancer activity in various cell lines. The molecules synthesized are of immense biological significance. This resulted in design and synthesis of new congeners as illustrated in  FIG. 1  which comprise:
         1. Formation of chalcone by reaction of imidazothiazole aldehyde of formula 5 (also see  FIG. 2 ) with acetophenones of formula 6 (also see  FIG. 3 ).   2. Stirring the reaction mixtures at room temperature 25-35° C. for 4 h in ethanol in the presence of 10% aqueous solution of NaOH.   3. Purification by column chromatography using different solvents like ethylacetate, hexane, dichloromethane and methanol.       

     EXAMPLES 
     The present invention will be more specifically explained by following examples. However, the scope of the present invention is not limited to the scope of these examples below. 
     Example 1 
     (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl) prop-2-en-1-one (7a) 
     To a stirred solution of trimethoxy acetophenone (210 mg, 1.0 mmol) and a 6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-carbaldehyde (258 mg, 1.0 mmol) in ethanol (20 ml) 10% aqueous solution of NaOH was added (5 ml). The reaction mixture was stirred at room temperature 27° C. for 4 h and the reaction was monitored by TLC using ethyl acetate-hexane (3:7) as a solvent system. The solvent was evaporated under vacuum then the residue was dissolved in ethylacetate/water. The organic layer was washed with brine and evaporated. This was further purified by column chromatography using ethyl acetate:hexane (2:8) as a solvent system to obtain the pure product (7a) as yellow solid (360 mg, 80% yield). Mp: 177-179° C. 
       1 H NMR (CDCl3, 200 MHz)             3.86 (s, 3H), 3.92 (s, 9H), 6.96-7.06 (m, 3H), 7.18 (s, 2H), 7.19 (d, 1H, J=15.51 .Hz), 7.66 (d, 1H, J=8.53 .Hz), 7.82 (d, 1H, J=3.87 .Hz), 8.04 (d, 1H, J=15.51 .Hz), ESI-MS: 451.51 (M+H) + .
     Example 2 
     (E)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (7e) 
     To a stirred solution of trimethoxy acetophenone (210 mg, 1.0 mmol) and a 6-(4-fluorophenyl)imidazo[2, 1-1)]thiazol-5-carbaldehyde (246 mg, 1.0 mmol) in ethanol (20 ml) 10% aqueous solution of NaOH was added (5 ml). The reaction mixture was stirred at room temperature 27° C. for 4 h and the reaction was monitored by TLC using ethyl acetate-hexane (3:7) as a solvent system. The solvent was evaporated under vacuum then the residue was dissolved in ethylacetate/water. The organic layer was washed with brine and evaporated. This was further purified by column chromatography using ethyl acetate:hexane (2:8) as a solvent system to obtain the pure product (7e) as yellow solid (328 mg, 75% yield). Mp: 222-225° C. 
       1 H NMR (CDCl3, 400 MHz)             3.89-3.92 (br, 9H) 7.05 (d, 1H J=4.39 Hz), 7.13 (s, 2H), 7.15 (d, 1H, J=15.38 .Hz), 7.17 (d, 1H, J=8.05 Hz), 7.24 (d, 1H, J=8.05 Hz), 7.70 (dd, 2H, J=5.12 Hz), 7.83 (d, 1H, J=4.39 Hz), 7.96 (d, 1H, J=15.38 Hz), ESI-MS: 439.47 (M+H) 4 .
     Example 3 
     (E)-3-(6-(trifluoromethyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one (7f) 
     To a stirred solution of trimethoxy acetophenone (210 mg, 1.0 mmol) and a 6-(trifluoromethyl)imidazo[2,1-b]thiazole-5-carbaldehyde (220 mg, 1.0 mmol) in ethanol (20 ml) 10% aqueous solution of NaOH was added (5 ml). The reaction mixture was stirred at room temperature 27° C. for 4 h and the reaction was monitored by TLC using ethyl acetate-hexane (3:7) as a solvent system. The solvent was evaporated under vacuum then the residue was dissolved in ethylacetate/water. The organic layer was washed with brine and evaporated. This was further purified by column chromatography using ethyl acetate:hexane (2:8) as a solvent system to obtain the pure product (70 as yellow solid (329 mg, 80% yield). Mp: 177-180° C. 
       1 H NMR (CDCl3, 300 MHz)             3.94-3.96 (b, 9H), 7.17 (d, 1H, J=15.86 Hz), 7.21-7.22 (b, 2H), 7.33 (d, 1H, J=5.86 Hz), 7.83 (d, 1H, J=4.53 Hz), 7.90 (d, 1H J=15.86 Hz), ESI-MS: 413.38 (M+H) + .
     Example 4 
     (E)-1-(3,4-dimethoxyphenyl)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one (8e) 
     To a stirred solution 3,4-dimethoxyphenyl acetophenone (180 mg, 2.7 mmol) and a 6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-carbaldehyde (246 mg, 2.7 mmol) in ethanol (20 ml) 10% aqueous solution of NaOH was added (5 ml). The reaction mixture was stirred at room temperature 27° C. for 4 h and the reaction was monitored by TLC using ethyl acetate-hexane (3:7) as a solvent system. The solvent was evaporated under vacuum then the residue was dissolved in ethylacetate/water. The organic layer was washed with brine and evaporated. This was further purified by columnchromatography using ethyl acetate:hexane (2:8) as a solvent system to obtain the pure product (8e) as yellow solid (306 mg, 75% yield). Mp: 221-223° C. 
       1 H NMR (CDCl3, 300 MHz)             3.96 (s, 6H), 6.90 (d, 1H, J=8.30 Hz), 7.07 (d, 1H, J=4.53 .Hz), 7.15-7.22 (m, 2H), 7.29 (d, 1H, J=15.86 Hz), 7.53-7.59 (m, 2H), 7.69-7.75 (m, 2H) 7.86 (d, 1H, J=4.53 Hz), 8.02 (d, 1H J=15.86 Hz), ESI-MS: 409.45 (M+H) + .
     Example 5 
     (E)-1-(3,4-dimethoxyphenyl)-3-(6-(trifluoromethyl)imidazo[2,1-b)]thiazol-5-yl) Prop-2-en-1-one (8f) 
     To a stirred solution 3,4-dimethoxyphenyl acetophenone (180 mg, 2.7 mmol) and a 6-(trifluoromethyl)imidazo[2,1-b]thiazole-5-carbaldehyde (246 mg, 2.7 mmol) in ethanol (20 ml) 10% aqueous solution of NaOH was added (5 ml). The reaction mixture was stirred at room temperature 27° C. for 4 h and the reaction was monitored by TLC using ethyl acetate-hexane (3:7) as a solvent system. The solvent was evaporated under vacuum then the residue was dissolved in ethylacetate/water. The organic layer was washed with brine and evaporated. This was further purified by columnchromatography using ethyl acetate:hexane (2:8) as a solvent system to obtain the pure product (80 as yellow solid (306 mg, 75% yield). Mp: 167-169° C. 
       1 H NMR (CDCl3, 300 MHz)             3.97 (s, 6H), 6.93 (d, 1H, J=9.065 Hz), 7.19 (d, 1H, J=4.53 .Hz), 7.41 (d, 1H, J=15.86 Hz), 7.57-7.61 (m, 2H), 7.83 (d, 1H, J=4.53 Hz), 7.91 (d, 1H J=15.86 Hz), ESI-MS: 382.35 (M+H) + .
     Example 6 
     (E)-1(3,5-difluorophenyl)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazo-5-yl)prop-2-en-1-one (10a) 
     To a stirred solution of 3,5 difluoro phenyl acetophenone (156 mg, 1.0 mmol) and a 6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-carbaldehyde (258 mg, 1.0 mmol) in ethanol (20 ml) 10% aqueous solution of NaOH was added (5 ml). The reaction mixture was stirred at room temperature 27° C. for 4 h and the reaction was monitored by TLC using ethyl acetate-hexane (3:7) as a solvent system. The solvent was evaporated under vacuum then the residue was dissolved in ethylacetate/water. The organic layer was washed with brine and evaporated. This was further purified by column chromatography using ethyl acetate:hexane (2:8) as a solvent system to obtain the pure product (10a) as yellow solid (364 mg, 92% yield). Mp: 234-236° C. 
       1 H NMR (CDCl3, 300 MHz)             3.87 (s, 3H), 7.0-7.08 (m, 3H), 7.02 (d, 1H, J=3.77 Hz), 7.07 (d, 1H J=15.86 Hz), 7.43-7.48 (m, 2H,) 7.65 (d, 2H, J=4.83 Hz), 7.87 (d, 1H, J=4.53 Hz), 8.09 (d, 1H, J=15.10 Hz), ESI-MS: 397.46 (M+H) + .
     Example 7 
     (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one (11a) 
     To a stirred solution 3,4-methylenedioxy phenyl acetophenone (164 mg, 1.0 mmol) and a 6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-carbaldehyde (258 mg, 1.0 mmol) in ethanol (20 ml) 10% aqueous solution of NaOH was added (5 ml). The reaction mixture was stirred at room temperature 27° C. for 4 h and the reaction was monitored by TLC using ethyl acetate-hexane (3:7) as a solvent system. The solvent was evaporated under vacuum then the residue was dissolved in ethylacetate/water. The organic layer was washed with brine and evaporated. This was further purified by column chromatography using ethyl acetate:hexane (2:8) as a solvent system to obtain the pure product (11a) as yellow solid (323 mg, 80% yield). Mp: 189-191° C. 
       1 H NMR (CDCl3, 200 MHz)             3.86 (s, 3H), 6.083 (s, 2H), 6.86 (d, 1H, J=8.08 Hz), 6.95-7.04 (m, 3H), 7.17 (d, 1H, J=15.42 Hz), 7.54-7.68 (m, 4H,) 7.84 (d, 1H, J=4.40 Hz), 8.03 (d, 1H, J=15.42 Hz), ESI-MS: 405.44 (M+H) + .
     Example 8 
     (E)-1-(3,4-dimethylphenyl)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one (9e) 
     To a stirred solution of 3,4-dimethylphenyl acetophenone (148 mg, 1.0 mmol) and a 6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-carbaldehyde (246 mg, 1.0 mmol) in ethanol (20 ml) 10% aqueous solution of NaOH was added (5 ml). The reaction mixture was stirred at room temperature 27° C. for 4 h and the reaction was monitored by TLC using ethyl acetate-hexane (3:7) as a solvent system. The solvent was evaporated under vacuum then the residue was dissolved in ethylacetate/water. The organic layer was washed with brine and evaporated. This was further purified by column chromatography using ethyl acetate:hexane (2:8) as a solvent system to obtain the pure product (9e) as yellow solid (286 mg, 76% yield). Mp: 210-213° C. 
       1 H NMR (CDCl3, 300 MHz)             2.34-2.36 (b, 6H), 7.06 (dd, 2H, J=4.53 Hz), 7.14-7.19 (m, 2H), 7.23 (d, 1H J=15.10 Hz), 7.22-7.27 (m, 3H), 7.65-7.74 (m,4H), 7.87 (d,1H,J=4.53 Hz) 7.99 (d,1H,J=15.10 Hz), ESI-MS: 377.45 (M+H) + .
     Example 9 
     (E)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(naphthalen-2-yl)prop-2-en-1-one (12e) 
     To a stirred solution of 2-acetyl napthalene (170 mg, 1.0 mmol) and a 6-(4-fluorophenyl) imidazo[2,1-b]thiazol-5-carbaldehyde (246 mg, 1.0 mmol) in ethanol (20 ml) 10% aqueous solution of NaOH was added (5 ml). The reaction mixture was stirred at room temperature 27° C. for 4 h and the reaction was monitored by TLC using ethyl acetate-hexane (3:7) as a solvent system. The solvent was evaporated under vacuum then the residue was dissolved in ethylacetate/water. The organic layer was washed with brine and evaporated. This was further purified by column chromatography using ethyl acetate:hexane (2:8) as a solvent system to obtain the pure product (12e) as yellow solid (298 mg, 75% yield). Mp: 216-218° C. 
       1 H NMR (CDCl3, 400 MHz)             6.34 (t, 2H, J=8.95 Hz), 6.62 (d, 1H J=15.22 Hz), 6.62 (d, 1H, J=4.47 Hz), 6.65-6.75 (m, 3H), 6.86-6.89 (d, 1H J=15.22 Hz), 6.96-7.02 (m, 2H), 7.08-7.15 (m, 2H), 7.71 (d, 1H J=4.47 Hz),7.87-7.89 (b,1H), ESI-MS: 399.45 (M+H) + .
     Example 10 
     (E)-1-(biphenyl-4-yl)-3-(6-(4-fluorophenyl)imidazo[2, 1-1)]thiazol-5-yl)prop-2-en-1-one (13e) 
     To a stirred solution of biphenyl acetophenone (196 mg, 1.0 mmol) and a 6-(4-fluorophenyl)imidazo[2,1-1)]thiazol-5-carbaldehyde (246 mg, 1.0 mmol) in ethanol (20 ml) 10% aqueous solution of NaOH was added (5 ml). The reaction mixture was stirred at room temperature 27° C. for 4 h and the reaction was monitored by TLC using ethyl acetate-hexane (3:7) as a solvent system. The solvent was evaporated under vacuum then the residue was dissolved in ethylacetate/water. The organic layer was washed with brine and evaporated. This was further purified by column chromatography using ethyl acetate:hexane (2:8) as a solvent system to obtain the pure product (13e) as yellow solid (360 mg, 85% yield). Mp: 194-196° C. 
       1 H NMR (CDCl3, 300 MHz)             7.10 (d, 1H, J=4.53 Hz), 7.16-7.22 (m, 2H), 7.31 (d, 1H, J=15.86 Hz), 7.38-7.51 (m, 4H), 7.63-7.65 (m, 1H), 7.70-7.75 (m, 4H), 7.91 (d, 1H, J=4.53 Hz), 8.03-8.07 (m, 2H), 8.08 (d,1H, J=15.86 Hz), ESI-MS: 425.49 (M+H) + .
     Example 11 
     (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(thiophen-2-yl)prop-2-en-1-one (16a) 
     To a stirred solution of 2-acetyl thiophene (126 mg, 1.0 mmol) and a 6-(4-methoxyphenyl) imidazo[2,1-b]thiazol-5-carbaldehyde (258 mg, 1.0 mmol) in ethanol (20 ml) 10% aqueous solution of NaOH was added (5 ml). The reaction mixture was stirred at room temperature 27° C. for 4 h and the reaction was monitored by TLC using ethyl acetate-hexane (3:7) as a solvent system. The solvent was evaporated under vacuum then the residue was dissolved in ethylacetate/water. The organic layer was washed with brine and evaporated. This was further purified by column chromatography using ethyl acetate:hexane (2:8) as a solvent system to obtain the pure product (16a) as yellow solid (256 mg, 70% yield). Mp: 169-172° C. 
       1 H NMR (CDCl3, 300 MHz)             3.86 (s, 3H), 7.01 (d, 1H J=15.86 Hz), 7.0-7.02 (bs, 2H), 7.13-7.17 (m, 2H),7.62-7.67 (m, 3H) 7.77 (d, 1H, J=3.02 Hz),7.84 (d, 1H, J=4.53 Hz), 8.05 (d, 1H, J=15.86 Hz), ESI-MS: 367.46 (M+H) + .
     Example 12 
     (E)-3-(6-(4-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one (17a) 
     To a stirred solution of 2-acetyl pyrrole (109 mg, 1.0 mmol) and a 6-(4-methoxyphenyl) imidazo[2,1-b]thiazol-5-carbaldehyde (258 mg, 1.0 mmol) in ethanol (20 ml) 10% aqueous solution of NaOH was added (5 ml). The reaction mixture was stirred at room temperature 27° C. for 4 h and the reaction was monitored by TLC using ethyl acetate-hexane (3:7) as a solvent system. The solvent was evaporated under vacuum then the residue was dissolved in ethylacetate/water. The organic layer was washed with brine and evaporated. This was further purified by column chromatography using ethyl acetate:hexane (2:8) as a solvent system to obtain the pure product (17a) as yellow solid (286 mg, 82% yield). Mp: 177-179° C. 
       1 H NMR (CDCl3, 300 MHz)             3.88 (s, 3H), 6.23-6.27 (m, 1H), 7.0-7.09 (m, 3H), 7.30 (d, 1H, J=16.09 Hz), 7.35-7.37 (m, 2H), 7.63 (d, 2H J=8.77 Hz), 7.90 (d,1H, J=16.09 Hz),8.45 (d,1H J=4.38 Hz), ESI-MS: 350.41 (M+H) + .
     Example 13 
     (E)-3-(6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxy-phenyl)trimethoxyphenyl)prop-2-en-1-one (19e) 
     To a stirred solution of trimethoxy acetophenone (210 mg, 1.0 mmol) and a 6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-carbaldehyde (260 mg, 1.0 mmol) in ethanol (20 ml) 10% aqueous solution of NaOH was added (5 ml). The reaction mixture was stirred at room temperature 27° C. for 4 h and the reaction was monitored by TLC using ethyl acetate-hexane (3:7) as a solvent system. The solvent was evaporated under vacuum then the residue was dissolved in ethylacetate/water. The organic layer was washed with brine and evaporated. This was further purified by column chromatography using ethyl acetate:hexane (2:8) as a solvent system to obtain the pure product (19e) as yellow solid (362 mg, 80% yield). Mp: 159-162° C. 
       1 H NMR (CDCl3, 400 MHz)             2.54 (s, 3H), 3.79 (s, 3H), 3.90 (s, 6H), 7.33 (s, 2H), 7.49 (d, 1H J=15.53 Hz), 7.67 (dd, 2H J=5.18 Hz), 7.82 (d, 1H J=15.53 Hz), 8.22 (s, 2H), 8.40 (s, 1H), ESI-MS: 453.56 (M+H) + .
     BIOLOGICAL ACTIVITY 
     Some of in vitro biological activity studies were carried out at the National Cancer Institute, Maryland, USA. 
     In Vitro Cytotoxicity 
     The imidazothiazole-chalcone hybrids 7a, 7e, 7f, 8f and 19e have been tested against sixty human tumour cell lines derived from nine cancer types (leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer) as per NCI protocol. For each compound, dose response curves for individual cell lines have been measured at a minimum of five concentrations at 10 fold dilutions. A protocol of 48 h continuous drug exposure has been used, and a sulforhodamine B (SRB) protein assay was used to estimate cell viability or growth. The concentration for 50% cell growth inhibition (GI 50 ), total cell growth inhibition (TGI, 0% growth) and 50% cell death (LC 50 , 50% growth) compared with the control has been calculated (Table-1). Compounds 7a, 7e, 7f, 8f and 19e have been evaluated for their in vitro cytotoxicity in sixty cell lines from nine human cancer types of lung (A549/ATCC, Hop-92, NCI-H226), leukemia cell lines (K-562, HL-60 (TB), colon cell lines (HCT-116, COLO 205, HCC-2998), CNS cell lines (SF-539), melanoma cell lines (SK-MEL-5, UACC-62, M14), ovarian cell lines (IGROV1), renal cell lines (CAKI-1), prostate cell lines (DU-145) and breast cell lines (BT-549, MDA-MB-435, HS578T) origin. The results are expressed as percent of cell growth determined relative to that of untreated control cells (Table 2). The representative compounds 7a, 7e, 7f, 8f and 19e have shown significant cytotoxicity against some cancer cell lines. 
     
       
         
               
             
               
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 1 
               
             
             
               
                   
               
               
                 Log 10  GI 50  (concentration in mol/L causing 50% growth inhibition) values for 
               
               
                 imidazothiazole-chalcone hybrids (7a, 7e, 7f, 8f and 19e) 
               
             
          
           
               
                   
                   
                 Non- 
                   
                   
                   
                   
                   
                   
                   
               
               
                   
                   
                 small- 
               
               
                   
                 Leukemia 
                 celllung 
                 Colon 
                 CNS 
                 Melanoma 
                 Ovarian 
                 Renal 
                 Prostate 
                 Breast 
               
               
                   
                   
               
             
          
           
               
                 Log 10   
                 −5.65 
                 −5.71 
                 −5.58 
                 −5.58 
                 −5.58 
                 −5.73 
                 −5.60 
                 −5.54 
                 −5.60 
               
               
                 GI50 
               
               
                 7a 
               
               
                 Log 10   
                 −4.00 
                 −4.02 
                 −4.14 
                 −4.00 
                 −4.15 
                 −4.15 
                 −4.00 
                 −4.00 
                 −4.00 
               
               
                 LC50 
               
               
                 7a 
               
               
                 Log 10   
                 −5.73 
                 −5.65 
                 −5.58 
                 −5.63 
                 −5.58 
                 −5.66 
                 −5.81 
                 −5.53 
                 −5.55 
               
               
                 GI50 
               
               
                 7e 
               
               
                 Log 10   
                 −4.15 
                 −4.25 
                 −4.42 
                 −4.28 
                 −4.37 
                 −4.28 
                 −4.06 
                 −4.00 
                 −4.00 
               
               
                 LC50 
               
               
                 7e 
               
               
                 Log 10   
                 −5.89 
                 −5.61 
                 −5.79 
                 −5.72 
                 −5.77 
                 −5.57 
                 −5.73 
                 −5.71 
                 −5.68 
               
               
                 GI50 
               
               
                 7f 
               
               
                 Log 10   
                 −4.00 
                 −4.57 
                 −5.07 
                 −4.90 
                 −5.03 
                 −4.24 
                 −4.98 
                 −4.70 
                 −4.61 
               
               
                 LC50 
               
               
                 7f 
               
               
                 Log 10   
                 −5.83 
                 −5.40 
                 −5.61 
                 −5.47 
                 −5.44 
                 −5.53 
                 −5.31 
                 −5.53 
                 −5.53 
               
               
                 GI50 
               
               
                 8f 
               
               
                 Log 10   
                 −4.00 
                 −4.00 
                 −4.00 
                 −4.00 
                 −4.00 
                 −4.00 
                 −4.00 
                 −4.00 
                 −4.00 
               
               
                 LC50 
               
               
                 8f 
               
               
                 Log 10   
                 −5.57 
                 −5.35 
                 −5.30 
                 −4.90 
                 −5.52 
                 −5.17 
                 −5.20 
                 −5.37 
                 −5.44 
               
               
                 GI50 
               
               
                 19e 
               
               
                 Log 10   
                 −4.00 
                 −4.00 
                 −4.00 
                 −4.00 
                 −4.00 
                 −4.00 
                 −4.00 
                 −4.00 
                 −4.00 
               
               
                 LC50 
               
               
                 19e 
               
               
                   
               
             
          
         
       
     
     Each cancer type represents the average of six to eight different cancer cell lines. 
     The compounds 7a, 7e, 7f, 8f and 19e exhibit a wide spectrum of activity against sixty cell lines in nine cell panels, with GI 50  value of &lt;9 μm. In the Leukemia cancer panel, the growths of SR cell lines were affected by compounds 7f, 8f and 19f with GI 50  values as 0.54, 0.49 and 0.80 μM respectively. In the non-small cell lung cancer panel, the growth of HOP-92 cell line was affected by compounds 7a, 7e and 19e with GI 50  values as 0.24, 1.05 and 0.15 μM respectively. The GI 50  values of compounds 7a and 7f against colon cancer HCC-2998, HCT-116 cell lines are 1.77, 1.88 and 1.71, 1.01 μM respectively. The GI 50  values for compounds 7a and 19e against melanoma SK-MEL-5 cell line are 1.30 and 0.51 μm respectively. The GI 50  value for compound 8f against melanoma LOX IMVI cell line is 0.60 μm. The GI 50  values for compounds 7a and 7e against ovarian cancer IGROV1 cell line are 0.21 and 1.04 μM respectively, and The GI 50  values for compound 7a against ovarian cancer OVCAR-5, OVCAR-8 cell lines are 1.99, 2.01 μM respectively. The GI 50  values for compounds 7a and 7e against renal CAKI-1 cell line are 1.20 and 0.04 μm respectively. The GI 50  values for compounds 7f and 8f against prostate cancer DU-145 cell line are 1.41 and 1.64 μm respectively. The GI 50  values for compounds 7f, 8f and 19e against breast cancer MCF7 cell line are 1.25, 0.76 and 1.81 μm respectively. 
     Compounds 7a, 7e, 7f, 8f and 19e exhibits activity against sixty cell lines in nine cancer cell panels with GI 50  values of &lt;9 μm. in vitro cytotoxicity of compounds 7a, 7e, 7f, 8f and 19e in selected cancer cell lines has been illustrated in Table 2. The average GI 50  values for each cancer panel of compounds 7a, 7e, 7f, 8f and 19e have been illustrated in Table2. 
     
       
         
               
             
               
               
               
               
               
               
             
               
               
               
               
               
               
             
           
               
                 TABLE 2 
               
             
             
               
                   
               
               
                 In vitro cytotoxicity of compounds 7a, 7e, 7f, 8f and 19e in sixty cancer cell lines 
               
             
          
           
               
                 Cancer 
                   
                   
                   
                   
                   
               
               
                 panel/cell line 
                 GI 50 (μm)7a 
                 GI 50 (μm)7e 
                 GI 50 (μm)7f 
                 GI 50 (μm)8f 
                 GI 50 (μm)19e 
               
               
                   
               
             
          
           
               
                 Leukemia 
                   
                   
                   
                   
                   
               
               
                 CCRF-CEM 
                 3.08 
                 2.23 
                 1.24 
                 2.33 
                 7.19 
               
               
                 HL-60(TB) 
                 1.66 
                 1.77 
                 1.83 
                 1.00 
                 2.8 
               
               
                 K-562 
                 1.72 
                 1.55 
                 1.74 
                 2.25 
                 5.46 
               
               
                 MOLT-4 
                 2.52 
                 2.07 
                 1.92 
                 2.22 
                 1.62 
               
               
                 SR 
                 2.33 
                 1.73 
                 0.54 
                 0.49 
                 0.80 
               
               
                 RPMI-8226 
                 — 
                 — 
                 1.08 
                 1.62 
                 2.32 
               
               
                 Non-small 
               
               
                 cell lung 
               
               
                 A549/ATCC 
                 2.21 
                 2.09 
                 3.44 
                 4.65 
                 9.34 
               
               
                 EKVX 
                 3.12 
                 2.74 
                 2.72 
                 4.43 
                 2.29 
               
               
                 HOP-62 
                 2.21 
                 2.25 
                 1.93 
                 6.00 
                 85.1 
               
               
                 HOP-92 
                 0.24 
                 1.05 
                 7.00 
                 5.8 
                 0.15 
               
               
                 NCI-H226 
                 2.58 
                 1.89 
                 2.17 
                 6.95 
                 9.58 
               
               
                 NCI-H23 
                 2.18 
                 2.49 
                 1.72 
                 2.78 
                 2.24 
               
               
                 NCI-H322M 
                 3.70 
                 3.63 
                 1.96 
                 3.17 
                 8.65 
               
               
                 NCI-H460 
                 2.70 
                 2.30 
                 1.65 
                 1.94 
                 3.87 
               
               
                 NCI-H522 
                 1.97 
                 2.32 
                 2.03 
                 2.91 
                 2.96 
               
               
                 Colon 
               
               
                 COLO 205 
                 2.52 
                 2.79 
                 1.94 
                 4.56 
                 4.94 
               
               
                 HCC-2998 
                 1.77 
                 2.11 
                 1.71 
                 5.07 
                 9.93 
               
               
                 HCT-116 
                 1.88 
                 2.33 
                 1.01 
                 1.40 
                 2.92 
               
               
                 HCT-15 
                 3.45 
                 2.94 
                 1.80 
                 2.54 
                 3.76 
               
               
                 HT29 
                 3.12 
                 2.84 
                 1.83 
                 2.01 
                 6.96 
               
               
                 KM12 
                 2.65 
                 2.30 
                 1.47 
                 1.97 
                 3.63 
               
               
                 SW-620 
                 3.16 
                 2.99 
                 1.67 
                 1.49 
                 5.34 
               
               
                 CNS 
               
               
                 SF-268 
                 2.89 
                 2.52 
                 1.74 
                 3.44 
                 15.2 
               
               
                 SF-295 
                 2.73 
                 1.80 
                 2.58 
                 3.14 
                 2.33 
               
               
                 SF-539 
                 1.66 
                 1.74 
                 1.55 
                 2.36 
                 6.23 
               
               
                 SNB-19 
                 3.54 
                 3.73 
                 2.67 
                 4.25 
                 87.8 
               
               
                 SNB-75 
                 2.29 
                 2.46 
                 1.87 
                 6.87 
                 50.1 
               
               
                 U251 
                 3.05 
                 2.18 
                 1.38 
                 1.87 
                 4.07 
               
               
                 Ovarian 
               
               
                 IGROV1 
                 0.21 
                 1.04 
                 2.66 
                 3.15 
                 8.71 
               
               
                 OVCAR-3 
                 2.23 
                 2.16 
                 1.86 
                 2.12 
                 3.66 
               
               
                 OVCAR-4 
                 4.05 
                 3.78 
                 3.05 
                 4.08 
                 2.28 
               
               
                 OVCAR-5 
                 1.99 
                 1.92 
                 — 
                 4.18 
                 &gt;100 
               
               
                 OVCAR-8 
                 2.01 
                 1.98 
                 3.08 
                 2.40 
                 4.94 
               
               
                 NCI/ADR- 
                 2.57 
                 2.10 
                 — 
                 1.88 
                 2.63 
               
               
                 RES 
               
               
                 SK-OV-3 
                 3.28 
                 3.02 
                 2.87 
                 3.41 
                 6.12 
               
               
                 Renal 
               
               
                 786-0 
                 2.58 
                 2.51 
                 1.76 
                 5.67 
                 8.88 
               
               
                 A498 
                 2.99 
                 2.73 
                 1.89 
                 7.58 
                 — 
               
               
                 ACHN 
                 4.08 
                 2.96 
                 1.82 
                 5.10 
                 5.83 
               
               
                 CAKI-1 
                 1.20 
                 0.04 
                 1.76 
                 2.46 
                 1.78 
               
               
                 RXF 393 
                 — 
                 — 
                 2.02 
                 2.51 
                 5.75 
               
               
                 SN12C 
                 2.88 
                 1.88 
                 1.56 
                 2.98 
                 9.01 
               
               
                 TK-10 
                 5.04 
                 5.81 
                 2.30 
                 8.76 
                 28.0 
               
               
                 UO-31 
                 1.12 
                 2.03 
                 1.87 
                 8.47 
                 2.95 
               
               
                 Prostate 
               
               
                 PC-3 
                 3.10 
                 3.43 
                 2.66 
                 5.39 
                 2.41 
               
               
                 DU-145 
                 2.62 
                 2.45 
                 1.41 
                 1.64 
                 7.52 
               
               
                 Breast 
               
               
                 MCF7 
                 2.02 
                 2.24 
                 1.25 
                 0.76 
                 1.81 
               
               
                 MDA-MB- 
                 2.55 
                 2.49 
                 2.92 
                 5.91 
                 5.38 
               
               
                 231/ATCC 
               
               
                 HS 578T 
                 1.90 
                 2.05 
                 — 
                 2.51 
                 8.29 
               
               
                 BT-549 
                 3.46 
                 3.76 
                 2.26 
                 3.25 
                 3.75 
               
               
                 T-47D 
                 2.26 
                 3.25 
                 2.12 
                 2.90 
                 2.93 
               
               
                 MDA-MB- 
                 2.96 
                 3.17 
                 — 
                 6.18 
                 2.38 
               
               
                 468 
               
               
                 Melanoma 
               
               
                 LOX IMVI 
                 2.42 
                 1.85 
                 1.36 
                 0.60 
                 2.50 
               
               
                 MALME- 
                 5.42 
                 8.27 
                 1.59 
                 5.92 
                 2.69 
               
               
                 3M 
               
               
                 M14 
                 2.33 
                 2.75 
                 — 
                 2.67 
                 5.12 
               
               
                 MDAMB- 
                 2.85 
                 1.82 
                 1.61 
                 1.85 
                 1.75 
               
               
                 435 
               
               
                 SK-MEL-2 
                 2.42 
                 2.52 
                 2.26 
                 4.08 
                 5.75 
               
               
                 SK-MEL-28 
                 4.11 
                 4.19 
                 1.69 
                 8.48 
                 7.07 
               
               
                 SK-MEL-5 
                 1.30 
                 1.45 
                 1.59 
                 4.20 
                 0.51 
               
               
                 UACC-62 
                 2.08 
                 1.82 
                 1.52 
                 4.85 
                 2.91 
               
               
                 UACC-25 
                 — 
                 — 
                 1.90 
                 7.77 
                 4.75 
               
               
                   
               
             
          
         
       
     
     The mean graph mid point values of log 10  TGI and log 10  LC 50  as well as log 10  GI 50  for 7a, 7e, 7f, 8f and 19e are listed in Table-3. As demonstrated by mean graph pattern, compounds 7a, 7e, 7f, 8f and 19e exhibit an interesting profile of activity and selectivity for various cell lines. The mean graph mid points of log 10  TGI and log 10  LC 50  have shown similar pattern to the log 10  GI 50  mean graph mid points. 
     
       
         
               
             
               
               
               
               
               
             
           
               
                 TABLE 3 
               
             
             
               
                   
               
               
                 log 10  GI 50 , log 10  TGI and log 10  LC 50  mean graphs midpoints (MG_MID) 
               
               
                 of in vitro cytotoxicity data for the compounds 7a, 7e, 7f, 8f and 
               
               
                 19e.against human tumour cell lines. 
               
             
          
           
               
                   
                 Compound 
                 Log 10  GI 50   
                 Log 10  TGI 
                 Log 10  LC 50   
               
               
                   
                   
               
               
                   
                  7a 
                 −5.63 
                 −4.76 
                 −4.06 
               
               
                   
                  7e 
                 −5.65 
                 −5.02 
                 −4.23 
               
               
                   
                  7f 
                 −5.72 
                 −5.28 
                 −4.72 
               
               
                   
                  8f 
                 −5.51 
                 −4.22 
                 −4.00 
               
               
                   
                 19e 
                 −5.32 
                 −4.14 
                 −4.02 
               
               
                   
                   
               
             
          
         
       
     
     
       
         
               
             
               
               
               
               
               
             
               
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 4 
               
             
             
               
                   
               
               
                 Comparative efficacy of Imidazothiazole-Chalcone derivatives of the present 
               
               
                 invention with Kown Chalcones &amp; Imidathiazole compounds. 
               
             
          
           
               
                   
                   
                 Di 
                 Boronic 
                   
               
               
                 Cancer 
                 Imidazothiazole- 
                 phenyl 
                 chalcones 
               
             
          
           
               
                 panel/cell 
                 Chalcones (μm) 
                 Chalcones 
                 Mono 
                 Di 
                 A 
                 B 
                 C 
               
             
          
           
               
                 line 
                 7a 
                 7e 
                 7f 
                 8f 
                 (μm) 
                 (μm) 
                 (μm) 
                 (μm) 
                 (μm) 
                 (μm) 
               
               
                   
               
               
                 HCT116 
                 1.88 
                 2.33 
                 1.01 
                 1.40 
                 — 
                 3.9 
                 1.5 
                 — 
                 — 
                 — 
               
               
                 MCF-7 
                 2.02 
                 2.24 
                 1.25 
                 0.76 
                 23.5 
                 — 
                 — 
                 21.5 
                 14.3 
                 32.5 
               
               
                 MDA- 
                 2.55 
                 2.49 
                 2.92 
                 0.76 
                 28.8 
                 — 
                 — 
                 25.8 
                 15.9 
                 43.2 
               
               
                 MB- 
               
               
                 231/ATCC 
               
               
                 HOP-92 
                 0.24 
                 1.05 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
               
               
                 IGROV1 
                 0.21 
                 1.04 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
               
               
                 CAKI-1 
                 1.20 
                 0.04 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
               
               
                   
               
               
                 A = 6-OMe-imidazothiazole 
               
               
                 B = 6-CF 3 -imidazothiazole 
               
               
                 C = imidazobenzothiazole 
               
             
          
         
       
     
     From The Table it is observed that, imidazothiazole linked chalcones have exhibited better anticancer activity than diphenyl chalcones (Food and Chemical Toxicology 44 (2006) 704-713) and boronic chalcones ( Mol Pharmacol  70:426-433, 2006) for some representative cancer cell lines (HCT116, MCF7, and MDA-MB-231/ATCC). Comparatively, diphenyl and boronic chalcones are very low active. Moreover, for other cancer cell lines also imidazothiazole linked chalcones have showed promising anticancer activity, their mechanism of action is under investigation. 
     Besides this, the chalcone derivatives of the present invention have shown significant anticancer activity compared to basic individual subunits, i.e., 6-OMe-imidazothiazole, 6-CF 3 -imidazothiazole and imidazobenzothiazoles as seen in Table-4. 
     Significance of the Work Carried Out 
     The imidazothiazole-chalcone hybrids that have been synthesized exhibited significant cytotoxic activity against sixty human tumour cell lines. 
     Advantages of the Invention 
     1. The present invention provides new imidazothiazole-chalcone hybrids of general formula A, useful as anticancer agents. 
     2. It also provides a process for the preparation of novel imidazothiazole-chalcone hybrids of general formula A.